CAR-T: What’s next? Part 2
In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a...
CAR-T: What’s next? Part 1
Over the last two months, several news events have brought CAR-T cells to widespread public attention, the most prominent of which is the...
Is Digital Health ever going to become mainstream?
I’ve been involved with Digital Health since 2012. At that time, the industry was espousing how Digital Health was ready to explode –...
